Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68-THP PSMA - NanoMab

Next Previous
Drug Profile

Gallium-68-THP PSMA - NanoMab

Alternative Names: (68)Ga-THP-PSMA - NanoMab; 68Ga-Labeled PSMA - NanoMab; 68Ga-THP-PSMA - NanoMab; Ga-68-THP-PSMA - NanoMab; Gallium-68 tris-hydroxypyridinone prostate specific membrane antigen - NanoMab; NM-03

Latest Information Update: 28 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoMab
  • Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in China (Injection)
  • 20 Nov 2019 Preclinical trials in Prostate cancer (Diagnosis) in China (Injection)
  • 20 Nov 2019 NanoMab in collaboration with Shanghai General Hospital plans a phase I trial for Prostate cancer (Diagnostic) in China (Injection) (NCT04158817)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top